Stock Events

Stock Events

Organovo

$2.04

86

+$0.03+1.49% Wednesday 20:00

+$0.00+0%Wednesday 23:43Pre-market

Statistics

Day High

2.16

Day Low

1.9399

52W High

21.96

52W Low

1.56

Volume

184,048

Avg. Volume

760,714

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

5NovExpected

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q4 2025

Q2 2026

Next

-2.52

-2.36

-2.2

-2.04

Expected EPS

N/A

Actual EPS

N/A

Financials

-13,459.63%Profit Margin

Unprofitable

2018

2019

2020

2021

2022

2023

109,000Revenue

-14.67MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Pfizer is involved in biopharmaceuticals and has investments in regenerative medicine and tissue engineering, competing in similar spaces as Organovo.

Novartis is a global healthcare company that engages in research and development in biotech and regenerative medicine, areas where Organovo also operates.

Merck operates in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Organovo's 3D bioprinting technologies.

Thermo Fisher Scientific

Thermo Fisher Scientific offers products and services in the life sciences field, including technologies that could compete with Organovo's bioprinting solutions.

Danaher is a global science and technology innovator with businesses in life sciences and diagnostics, potentially competing with Organovo's offerings.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals focuses on regenerative medicine and biotechnology, directly competing with Organovo's research and development in 3D bioprinting.

Illumina provides genomics solutions, which could be used in conjunction with or in competition to Organovo's bioprinting technologies for personalized medicine.

Bio-Rad Laboratories

Bio-Rad Laboratories offers products and services in the life science research and clinical diagnostics markets, potentially competing with Organovo's technologies.

Stryker is a medical technologies firm with products that could compete with Organovo's in areas such as surgical applications and regenerative medicine.

About

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Show more...

CEO

Mr. Keith E. Murphy

Employees

14

Country

United States

ISIN

US68620A1043

Listings

0 Comments

Share your thoughts

FAQ

What is Organovo stock price today?▼

The current price of ONVO is $2.04 USD — it has increased by +1.49% in the past 24 hours. Watch Organovo stock price performance more closely on the chart.

What is Organovo stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Organovo stocks are traded under the ticker ONVO.

What is Organovo revenue for the last year?▼

Organovo revenue for the last year amounts to 109,000 USD.

What is Organovo net income for the last year?▼

ONVO net income for the last year is -14.67M USD.

How many employees does Organovo have?▼

As of September 04, 2026, the company has 14 employees.

In which sector is Organovo located?▼

Organovo operates in the Health & Wellness sector.

When did Organovo complete a stock split?▼

The last stock split for Organovo was on March 21, 2025 with a ratio of 1:12.

Where is Organovo headquartered?▼

Organovo is headquartered in San Diego, United States.